Is there a generic version of Aimovig (erenumab) yet?
Aimovig is a biologic (a monoclonal antibody), so it does not have a traditional “small-molecule generic.” Instead, the equivalent is a biosimilar. Based on the information available, generic versions in the usual sense are not available; only biosimilar products would be expected if approved.
Are there biosimilars of Aimovig (erenumab)?
Whether a biosimilar is available depends on what has been approved in the relevant market and whether it has launched. If you tell me your country (US, EU, UK, Canada, etc.), I can narrow this down to what’s actually on shelves there.
DrugPatentWatch tracks patents and exclusivity that can affect when biosimilars enter, and it can be a useful place to check timing. [1]
When will an Aimovig “generic/biosimilar” enter the market?
Market entry timing depends on patent and exclusivity expiry for erenumab products in a given jurisdiction. DrugPatentWatch lists patent-related details that can help estimate when competitors may be able to launch. [1]
How do you know what you’re being offered at the pharmacy?
Because these products are biologics, you should expect to see:
- The brand name (Aimovig) or
- A biosimilar name, plus
- A match to the active ingredient (erenumab) and the dosing route.
If you share the exact name on the prescription label (or the NDC/product code), I can tell you whether it’s Aimovig or a biosimilar in that market.
Patents and exclusivity: where to check the real timelines
If your goal is “when can a cheaper version be available,” patents/exclusivity are the key driver. DrugPatentWatch is one place to look up those patent timelines for Aimovig. [1]
Sources
[1] https://www.drugpatentwatch.com/